Suppr超能文献

一项关于比马前列素和拉坦前列素降低眼压的昼夜反应率的随机、研究者设盲比较研究。

A randomized, investigator-masked comparison of diurnal responder rates with bimatoprost and latanoprost in the lowering of intraocular pressure.

作者信息

Choplin Neil, Bernstein Paula, Batoosingh Amy L, Whitcup Scott M

机构信息

Eye Care of San Diego, San Diego, California, USA.

出版信息

Surv Ophthalmol. 2004 Mar;49 Suppl 1:S19-25. doi: 10.1016/j.survophthal.2003.12.016.

Abstract

In glaucoma and ocular hypertension, clinically relevant intraocular pressure lowering due to a new medication is frequently defined as at least a 15% or 20% reduction from baseline intraocular pressure. This report compares the percentages of treated patients achieving such reductions in intraocular pressure after 6 months of treatment with bimatoprost or latanoprost. In the previously published study (Noecker et al: A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol 135:55-63, 2003), patients with glaucoma or ocular hypertension were randomly assigned to once-daily treatment with bimatoprost 0.03% (n=133) or latanoprost 0.005% (n=136), after washout of any previous glaucoma medications. The primary outcome measure of that study was mean change from baseline intraocular pressure. The secondary, post hoc analysis presented here compares the diurnal and long-term responder rates observed with bimatoprost and latanoprost patients. Diurnal responders were defined as patients who achieved at least a 15% or 20% reduction from baseline intraocular pressure at each of the three timepoints (8 am, 12 pm, and 4 pm) on a given visit. At week 1 and months 1, 3, and 6, in the bimatoprost group, 70.7-81.2% of patients achieved at least a 15% reduction in IOP at each timepoint, and 57.9-68.4% achieved at least a 20% reduction. Significantly fewer patients receiving latanoprost achieved a 15% or a 20% decrease in IOP at each timepoint: 48.5-61.8% of patients achieved at least a 15% decrease and 36.0-47.1% achieved at least a 20% decrease. (P< or =.007). The data presented here suggest that patients using bimatoprost are more likely than patients using latanoprost to achieve intraocular pressure reductions of at least 15% or 20% from baseline throughout the day.

摘要

在青光眼和高眼压症中,一种新药导致的具有临床意义的眼压降低通常被定义为眼压较基线水平至少降低15%或20%。本报告比较了使用比马前列素或拉坦前列素治疗6个月后眼压降低达到上述幅度的患者百分比。在先前发表的研究中(诺克等人:一项比较比马前列素和拉坦前列素对高眼压症或青光眼患者降眼压疗效的为期6个月的随机临床试验。《美国眼科杂志》135:55 - 63,2003年),青光眼或高眼压症患者在停用之前的任何青光眼药物后,被随机分配接受每日一次的0.03%比马前列素治疗(n = 133)或0.005%拉坦前列素治疗(n = 136)。该研究的主要结局指标是眼压相对于基线水平的平均变化。此处呈现的次要事后分析比较了比马前列素组和拉坦前列素组患者的日间和长期反应率。日间反应者定义为在某一特定就诊时,在三个时间点(上午8点、中午12点和下午4点)眼压均较基线水平至少降低15%或20%的患者。在第1周以及第1、3和6个月时,比马前列素组中,70.7 - 81.2%的患者在每个时间点眼压至少降低了15%,57.9 - 68.4%的患者眼压至少降低了20%。接受拉坦前列素治疗的患者在每个时间点眼压降低15%或20%的比例明显更低:48.5 - 61.8%的患者眼压至少降低了15%,36.0 - 47.1%的患者眼压至少降低了20%。(P≤0.007)。此处呈现的数据表明,与使用拉坦前列素的患者相比,使用比马前列素的患者全天眼压从基线水平降低至少15%或20%的可能性更大。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验